ABSTRACT Background/aims To present a new method to determine dose depth and the distance from the concave side of the plaque to the tumour base in patients with uveal melanoma treated with ruthenium-106 based on ultrasonic mirror image. Methods We used the mirror image associated with ultrasound during plaque brachytherapy to determine intraobserver reproducibility and interobserver agreement between two surgeons. 230 eyes with primary uveal melanoma were included in a retrospective analysis to determine the distance from the plaque to the tumour base using ultrasound. A phantom study was used to illustrate the effects on radiation dose to apex of the tumour when the dose depth was incorrectly determined. Doses to apex of the tumour were determined using Plaque Simulator. Results The intraobserver variation in dose depth measurement with plaque was significantly lower than for measures without plaque ( p<0.001). Agreement between the surgeons was better with a plaque in place. Distances from the plaque to the tumour base were distributed with mean=0.99 (median: 1, range: 0
INTRODUCTION
Ruthenium-106 (Ru-106) brachytherapy is widely used for patients with uveal melanomas (UM) as eye-salvaging treatment. [1] [2] [3] [4] To ensure sufficient radiation to the tumour with minimal damage to adjacent tissue, it is crucial that dose depth determination is accurate. 2 3 5-7 Internal reflectivity, tumour size ( figure 1A ) and correct positioning of the plaque (figure 1B) can be evaluated by ultrasonography B-scans. 2 8-12 Dose calculations are often based on these ultrasound measurements and include tumour height, scleral thickness and potential contribution from extraocular tissue such as muscle insertions and blood vessels: Dose depth ¼ tumour height þ scleral thickness þ extraocular tissue ð1Þ
Due to the three-dimensional shape of the tumour, it is challenging to measure the correct dose depth with the two-dimensional ultrasound method. Conventionally, dose depth is measured from apex of the tumour perpendicular onto the tumour base and 1 mm is added as this is assumed to be the scleral thickness. 3 11 13 However, in a normal eye, scleral thickness varies and is thickest at the posterior pole (1 mm) and thinnest behind the rectus muscle insertions (0.3 mm). 14 15 Furthermore, scleral thicknesses vary between individuals, a statement possibly related to refractive variation (higher myopia, longer eyes and a thinner sclera; higher hyperopia, shorter eyes and a thicker sclera). 16 This probably also underlies the gradually increase with age. 15 A standard scleral thickness may thus be incorrect for many eyes and may result in incorrect delivery of dose to the apex of the tumour. Furthermore, extraocular tissue and postoperative bleeding may contribute to an increased distance between the plaque and the tumour.
11
A new perioperative method for measuring the dose depth has been developed at the ophthalmic oncology service at Rigshospitalet: B-scan patterns perpendicular to the plaque often show a mirror image (MI), represented as a brighter flare from the plaque surface behind the eye, with the profile of the intraocular tumour surface partly mimicked behind the retrobulbar line. The MI is a result of transmitted and forward scattered sound encountering the plaque. When the focused soundwave encounters the tumour, some is backscattered to create its primary conventional image. The transmitted sound is reflected from the plaque, visualising the tumour again by sound scattered backward, and reflected a second time from the plaque to create the MI. The MI occurs equidistant behind the plaque and the signal from the MI is maximised where the sound beam is perpendicular to the plaque ( figure 1B-D) . A minimal fraction of sound scattered in other directions contributes to the image. 17 18 We propose that this new ultrasonography method using MI can be used to reduce uncertainties and increase reproducibility and agreement between surgeons in the dose depth measurements. We retrospectively examined the distance from the concave side of the plaque to the tumour base in a cohort of patients treated at our institution. Finally, the effect of incorrect determination of dose depth on the minimum dose to apex of the tumour was explored.
METHODS

Scanning technique
The transducer was placed with the scan plane vertical and pivoted around the centre of the eye in the horizontal plane to locate the maximum tumour height perpendicular to the ultrasound beam. Subsequently, the transducer was translated to maximise the underlying echo from the plaque and the image was frozen and stored. The manoeuvre was repeated with the transducer scan plane horizontal. Only cases where the maximal heights were identical in both vertical and horizontal scans through the tumour apex were considered for dose depth measurements.
Reproducibility of dose depth determination
Intraobserver reproducibility was determined from three repeated measures of dose depth made by a single experienced ophthalmologist on 10 human eyes with and without a plaque in place, and from three repeated in vitro ultrasound measurements on two porcine eyes with an artificial tumour (see below) with and without a plaque in place made by two experienced ophthalmologists.
Interobserver agreement between two surgeons was determined from the same two porcine eyes with and without a plaque in place on both porcine eyes. One eye was scanned twice by one surgeon making a total of five ultrasonographs with and five ultrasonographs without plaque available for measurements. Threefold repeated measures were made by each surgeon on each of the ultrasonographs leading to a total of 60 measurements. The height without plaque was determined from the apex perpendicular onto the base of the tumour. After placement of the plaque, the dose depth was estimated from the MI (Eq. 2).
The enucleated porcine eyes were kept in saline water for approximately 24 hours before use. Approximately 0.5 cm 3 Healon GV from Abbott Medical Optics was injected in the suprachoroidal space to produce a tumour. An incision was made 2 mm behind limbus, and blunt dissection in the suprachoroidal space was performed using a sub-Tenon cannula (KD Medical GmbH, Berlin, Germany). Ultrasound system Ellex Eye Cubed with a posterior segment 10 MHz probe (Adelaide, Australia) was used for measurements.
Acoustic shadowing and MI appeared only simultaneously with perpendicular propagation of the ultrasound onto the plaque. This ensured that the obtained image represented the structures in the central axis of the plaque. The double dose depth could be identified as the distance from tumour apex of the actual tumour to apex of the mimicked tumour ( figure 1C ). The actual dose depth was calculated as half of the double dose depth.
Dose depth = double dose depth/2 ð2Þ
Intraobserver reproducibility was evaluated by comparing measurement variances with and without the plaque in place: for each image separately, the mean of the three measures was calculated, and this mean value was subtracted from the three individual measures. The total variance for all adjusted measures for a single setting (eg, porcine eyes with plaque in place) was then estimated. Fligner-Killeen test for homogeneity between variances was used to compare measurement variation with and without the plaque in place. Agreement between the two surgeons was evaluated by a two-way model of intraclass correlation coefficient (ICC) for single measures.
Retrospective analyses of UM
In total, 230 eyes with primary UM (in the choroid or the ciliary body) were included in a retrospective analysis of dose depth determination using ultrasound. Patient and tumour characteristics are listed in at Rigshospitalet, Denmark. Plaque insertions were performed in the operating theatre under sterile conditions and general anaesthesia. We used Ru-106 plaques in different sizes and shapes (CCA plaque, CCB plaque, CCC plaque, and COB plaque), all supplied by Eckert & Ziegler BEBIG (GmbH, Berlin, Germany). The surgeries were done by three experienced ophthalmologists during the entire period.
We used posterior segment 10 MHz probes for all the examinations. In the first 112 patients, an I3-ABD System (Innovative Imaging, Sacramento, California, USA) was used. In the latter 118 patients, the same probe but a new machine (Ellex Eye Cubed, Adelaide, Australia) was used as the I3 Company was bought up by Ellex. Ultrasonic posterior B-scans were recorded in all eyes before and immediately after plaque insertion. All patients had additional scans performed one day after surgery to ensure plaque position. The MI was assessed in all of the 230 included eyes.
Combining Equations 1 and 2 yields double dose depth=2 ¼ tumour height þ scleral thickness þ extraocular tissue ð3Þ
Tumour heights were identified and measured from the apex to the base of the tumour in the recorded ultrasound images (figure 1B), while the double dose depths were determined from the MI ( figure 1C) . The distances between the concave side of the plaque and the tumour base that consist of the sclera and extraocular tissue are thus calculated as
Equation 4 allows the distance from plaque to tumour base to be calculated and evaluated for all eyes included in the cohort study.
Relation between gender and distance from plaque to tumour base was examined using a Mann-Whitney U test, and Spearman's correlation coefficient was used for correlation with age.
Simulation of effects of incorrect determination of dose depth on tumour dose distributions
A phantom study was used to illustrate the effects on radiation dose to apex of the UM when the dose depth was incorrectly determined. We prescribed 100 Gy to the apex of the phantom tumour with an assumed scleral thickness of 1 mm. At a range of scleral thicknesses (0.3, 0.4 … 1.7 mm), the actual minimum apex dose was determined. The study was simulated with a standard sized spherically dome-shaped tumour with base dimension of 10×10 mm and varying heights (1, 2, 3, 4 and 5 mm, respectively) using Plaque Simulator (V.6.1.3, EyePhysics LLC, Eckert & Ziegler BEBIG GmbH). A CCB plaque was used in this phantom study. Finally, four different plaque types (CCA plaque, CCB plaque, CCC plaque, and COB plaque) were used to irradiate a standard sized (10×10×5 mm) tumour in order to examine differences between plaques.
RESULTS
The intraobserver variation in dose depth measurement with Ru-106 plaque was significantly lower than for measures without plaque (p<0.001), in both human and porcine eyes, indicating a better reproducibility of measurements when done with the plaque in place. The top boxplot in figure 2 illustrates the differences from the mean distance for each of the three repeated measurements on 10 human eyes (n=30) before and after placement of the Ru-106 plaque. The middle boxplot shows variation from repeated measurements with and without plaque on two different porcine eyes performed by two experienced surgeons. Figure 2 Top: boxplot from repeated measurements on 10 human eyes with and without plaque. Middle: boxplot from repeated measurements from two individual surgeons made on two porcine eyes with and without plaque. Bottom: agreement between surgeons with and without plaque based on the mean from three repeated measures. E1, eye 1; E2, eye 2; S1, surgeon 1; S2, surgeon 2; w/o, without plaque; w, with plaque.
ICC from the measurements without Ru-106 plaque sutured to the porcine eye was 0.63 (95% CI −0.07 to 0.95), while ICC with plaque was 0.99 (95% CI 0.93 to 1). Agreement between the surgeons is better with a plaque in place, illustrated in figure 2 bottom.
Distances from the plaque to tumour base were calculated in the retrospective human cohort from Equation 4. The mean distance was 0.99 mm (median: 1 mm, range: 0.1-2.9 mm), but the distances were not normally distributed ( figure 3) .
There was no relation between distance from plaque to tumour base and gender ( p=0.67), nor any correlation with age ( p=0.99).
Minimum dose to apex of the tumour as a function of scleral thickness is shown left in figure 4 for each of the tumour heights.
As scleral thickness increases from 0.1 to 1.7 mm, the minimum dose delivered to the apex of the tumour tapered off from approximately 130 to 80 Gy. In the left plot in figure 4 , the standard sized tumour was irradiated with four different plaque types but delivered dose showed the same pattern for all plaques.
DISCUSSION
In the present study, we used the ultrasonic MI to measure the double dose depth in patients with UM as well as in porcine eyes. The reproducibility and agreement between two individual surgeons improved considerably as a result of the new method, which uses well-defined ultrasound echoes from the tumour surface and its reflected image in contrast to the conventional method with a poorly defined echo at the base. Furthermore, the new method alleviates the conventional arbitrary assumption of distance of 1 mm from the tumour base to the plaque. Hence, precision and accuracy of dosimetry is improved.
The proposed use of ultrasonic MI is an addition to already established surgical techniques, which need no alteration. Also, MI is a known phenomenon associated with ultrasound imaging. The ultrasonography method primarily provided information about plaque borders and location from the plaque shadow. Additionally, it refines the estimate of tumour height as the MI only occurs when the soundwave is perpendicular to the plaque. In obstetric ultrasonography, Ahn et al 19 described MI to consist of two similar imaging configurations separated with equal distance from the reflective interface. Ahn et al 19 further described the duplicated image to be blurred compared with the actual image. This is in agreement with our ultrasonographs.
The B-scan probe was used to optimise the transducer position and insonification angle. The greater dynamic resolution of an unfocused A-scan transducer had no advantage for determining the transit times of the reflected sound pulses. Furthermore, it proved very difficult and time consuming to assure perpendicular angles to the tumour top and the plaque simultaneously.
The agreement analysis is carried out based on the assumption that the clinically used measure of dose depth is calculated from the mean of three measurements by the ophthalmologist at each treatment. This is the ideal set-up in clinical practice to ensure the most correct measure for the dose depth. Since the true measure is unknown, we can only consider similarity between the two observers. The MI from the Ru plaque on ultrasonography gives a more reproducible measure of the dose depth. The CIs do not overlap, indicating significant differences between the measurements with and without plaques.
Distances from the plaque to the tumour base varied considerably among patients, showing a range from 0.1 to 2.9 mm. We found that in 52 of the patients (23%) the distance was in the interval from 0.91 to 1.1 mm, in accordance with the normally assumed 1 mm. Consequently, the distance differed from the otherwise generally accepted 1 mm in 77% of the patients. A single cause for the larger distance was not obvious, but it could possibly be explained by additional scleral tissue including muscle insertions, blood vessels or connective tissue, primarily posterior Tenon's capsule, which all contribute to additional dose depth when the plaque appears displaced by such structures. Postoperative bleeding also may force the plaque away from the eye wall and result in an increased dose depth ( figure 1D ). This was only the case in two patients in the present patient cohort. Gender and age showed no relation to dose depth. These findings Figure 3 Histogram of distances from plaque to tumour base. Figure 4 Left: minimum dose to tumour apex as a function of sclera thickness from a CCB plaque for tumour heights 1-5 mm. Right: minimum dose to tumour apex as a function of sclera thickness from four different plaque types for a 5 mm tumour.
are in accordance with Vurgese et al, 20 who reported same scleral thickness in men and women. One could speculate that atrophy of connective tissue would be more prominent with age, but this found no support in our study.
From the phantom study (figure 4), it is clear that the tumour does not receive the prescribed 100 Gy if the scleral thickness exceeds 1 mm. Conversely, a too large dose is delivered to the tumour, and adjacent radiation-sensitive structures (like the macula), if the factual scleral thickness is less than 1 mm. This emphasises that it is necessary to measure dose depth specifically for each patient to ensure correct calculation of dosage. Figure 4 further demonstrates that type of plaque has minimal influence on the delivered dose compared with the distance from the plaque to the tumour apex, and we thus identified no significant change between plaque sizes.
Knowledge of the correct dose depth is pertinent during Ru-106 treatments due to the steep radiation dose gradient. From the MI, the dose depth can be confirmed with higher precision than previously and help improving the dose calculation. The technique described in this paper has been developed based solely on patients treated with Ru-106 plaques, and this method may not be directly translated to the use of seeded plaques.
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